Clinical Trials
2,760 trialsSTARTRK-2
Hoffmann-La Roche
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
Dana-Farber Cancer Institute
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
Wake Forest University Health Sciences
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
ORCHID
Fudan University
ABBY
Abramson Cancer Center at Penn Medicine
CAMERAN
UNC Lineberger Comprehensive Cancer Center
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Hoffmann-La Roche
Probiotics for Abemaciclib-Induced Abdominal Discomfort.
Leeuwenhoek Laboratories Co. Ltd.
Efficacy and Safety of 500mg of Fulvestrant
Beth Israel Deaconess Medical Center
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer
National Cancer Institute (NCI)
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Acupuncture Pilot Study for Cancer-related Cognitive Function
Memorial Sloan Kettering Cancer Center
TIBET
Borstkanker Onderzoek Groep
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
SCRI Development Innovations, LLC
SEQUEL-Breast
Borstkanker Onderzoek Groep
A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer
Eisai Inc.
DIAMOND
Queen Mary University of London
preEMBER
Eli Lilly and Company
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
Memorial Sloan Kettering Cancer Center
A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)
M.D. Anderson Cancer Center
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
National Cancer Institute (NCI)
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Merck Sharp & Dohme LLC
Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer
City of Hope Medical Center
Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer
M.D. Anderson Cancer Center
EVOLVE-BDT
UNC Lineberger Comprehensive Cancer Center
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
NRG Oncology
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
Fudan University
ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer
Dana-Farber Cancer Institute
Study of Screening Brain MRIs in Stage IV Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Study of 18F-FFNP Breast PET/MRI
University of Wisconsin, Madison
LITESPARK-029
Merck Sharp & Dohme LLC
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Hoffmann-La Roche
GATHER
Centre Henri Becquerel
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
NeoTOP
Sun Yat-sen University
EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial
M.D. Anderson Cancer Center
RIBOLARIS
SOLTI Breast Cancer Research Group
A Study of Blood Pressure Control During Cancer Treatment
Memorial Sloan Kettering Cancer Center
A Study of Surgery and Radiotherapy in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
COMBINE-01
European Institute of Oncology
N01-A-PICIT-GT
Peking University People's Hospital
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
Dana-Farber Cancer Institute
A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause
University of Miami
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
National Cancer Institute (NCI)
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
National Cancer Institute (NCI)
HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy
Washington University School of Medicine